Why the study?
Does the combination of recombinant human alpha interferon and acyclovir improve survival in mice with lethal systemic herpes simplex virus type 1 infection compared to either agent alone?
Does the combination of recombinant human alpha interferon and acyclovir improve survival in mice with lethal systemic herpes simplex virus type 1 infection compared to either agent alone?
The combination of recombinant human alpha interferon and acyclovir shows synergistic activity in improving survival in a mouse model of lethal HSV-1 infection.
Answers are grounded in this paper and cite their sources.
Does not support clinical HSV-1 use; leaves open translation of murine synergy to human trials.
The nucleoside analog acyclovir [9-(2-hydroxyethoxymethyl)guanine] and the hybrid recombinant human alpha interferon (rHuIFN-alpha A/D) were evaluated in weanling mice for their efficacy alone and in combination against a lethal systemic infection with herpes simplex virus type 1. Simultaneous parenteral treatment with combinations of both agents at various doses resulted in a higher percentage of survival than when either agent was administered alone, with a synergistic interaction demonstrated at certain dose combinations. Sequential administration of parenteral rHuIFN-alpha A/D and oral acyclovir, administered by gavage or supplied ad libitum in drinking water, resulted in a synergistic interaction at all dose combinations tested. These results suggest that combinations of interferon and acyclovir may be useful in treating primary herpes simplex virus infections in humans.
No takes yet. Share an insight, caveat, or question.
Connell et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: